Analysis of Patent US6,730,288: Scope, Claims, and Patent Landscape
What is the scope of Patent US6,730,288?
Patent US6,730,288 covers a composition and method for manipulating the pharmacokinetics of a pharmaceutical compound, specifically relating to the controlled release of drugs. Filed in 2000 and granted in 2004, the patent focuses on a bioerodible polymer-based delivery system designed to release active agents over extended periods.
The patent's primary invention involves a matrix or coating comprising bioerodible polyesters, such as poly(lactic-co-glycolic acid) (PLGA). This matrix encapsulates the active pharmaceutical ingredient (API), allowing for sustained release—ranging from days to weeks—by degrading in physiological environments.
The patent's claims span compositions containing specific ratios of polymers and APIs, as well as methods of manufacturing such controlled-release formulations. The claims explicitly describe:
- The polymer compositions, including molecular weights and ratios.
- The manufacturing process, such as solvent evaporation.
- Specific API loadings and release profiles.
The scope does not extend to implantable devices beyond the described matrix systems or to non-polymer-based delivery mechanisms.
What are the key claims of Patent US6,730,288?
Independent Claims Overview
Claim 1: Describes a bioerodible composition comprising:
- A polymer matrix of bioerodible poly(lactic-co-glycolic acid) with defined molecular weight ranges.
- An active agent dispersed within the matrix.
- A specified API loading, typically within 10–40% weight.
- The matrix designed to release the API in a controlled manner over a period of at least one week.
Claim 2: Focuses on the method of preparing the composition via solvent evaporation, emphasizing parameters like solvent type and drying conditions.
Claim 3: Covers the use of the composition for sustained release of the API in a subject.
Dependent Claims
Dependent claims specify particular embodiments, including:
- Specific ratios of lactic acid to glycolic acid in the polymer (e.g., 75:25, 50:50).
- APIs such as corticosteroids or antiparasitics.
- Particle sizes and manufacturing temperatures.
Claim Scope Summary
The claims are centered on compositions of bioerodible polymers with specified parameters and methods for manufacturing them, aimed at achieving controlled drug delivery.
What does the patent landscape look like surrounding US6,730,288?
Patent Families and Related Patents
The patent is part of a family involving multiple filings and equivalents across jurisdictions. Key related patents include:
- US6,720,071 and US6,680,949, which address alternative biodegradable polymers and delivery methods.
- European Patent EP1,310,031, citing similar compositions adapted for different jurisdictions.
- Japanese Patent JP2005150194, with comparable polymer systems.
Patent Citations
Backward citations include foundational patents on bioerodible polymers and controlled release systems, such as:
- US4,857,302 (resorbable polymer matrices)
- US5,399,363 (poly(lactic-co-glycolic acid) formulations)
- US5,728,616 (controlled-release drug delivery devices)
Forward citations (post-grant references) include patents focused on specific API formulations, implantable microdevices, and newer polymer systems. For example:
- US7,420,293 focuses on implantable biodegradable microspheres.
- US8,674,321 describes lipid-based controlled-release systems.
Patent Trends and Developments
- Increasing focus on nanostructured polymer systems for enhanced bioavailability.
- Diversification into multi-drug delivery matrices.
- Integration with targeting ligands for site-specific release.
Patent Challenges and Litigation
No major litigation exists specifically targeting US6,730,288. However, it faces potential legal challenges based on prior art in biodegradable polymer systems. Its broad claims on polymer ratios and manufacturing processes could be scrutinized for obviousness in light of the cited prior art.
Summary of Patent Landscape Implications
The patent sits within a mature but still active field of biodegradable polymer-based drug delivery. Its claims are broad enough to cover significant variants, but narrowing patent rights alone cannot exclude all alternatives, especially newer polymer compositions and delivery systems.
Key Takeaways
- US6,730,288 covers specific bioerodible polymer compositions and their methods of manufacture for controlled drug release.
- The patent's claims focus on polymer ratios, molecular weights, API loadings, and preparation techniques.
- The surrounding patent landscape includes foundational patents on bioerodible systems, with recent activity in nanotechnology and multi-drug matrices.
- Legal challenges could arise from prior art, especially in the evolving biodegradable polymer field.
- Its broad claims may support future formulations but could be limited in scope by narrower subsequent patents.
FAQs
1. What is the main innovation of US6,730,288?
It specifies a bioerodible polymer matrix, primarily based on poly(lactic-co-glycolic acid), with particular polymer ratios and methods to achieve controlled release of APIs over extended periods.
2. How does the patent impact drug formulation development?
It provides a framework for creating sustained-release formulations using biodegradable polymers, influencing products such as injectable depots and implantable devices.
3. Are there similar patents that could compete with US6,730,288?
Yes, earlier patents on biodegradable polymers (e.g., US4,857,302, US5,399,363) and newer ones focused on nanocarrier systems. These could serve as prior art or alternatives.
4. Is the patent still enforceable?
Given its expiration in 2020 (20-year term from application date of 2000), the patent is no longer enforceable, opening the field for generic or biosimilar developers.
5. What are current trends in biodegradable polymer patents?
Focus areas include nanostructured polymers, multi-drug delivery systems, and targeted therapies integrating bioerodible matrices with targeting ligands.
References
- U.S. Patent and Trademark Office. Patent US6,730,288.
- Grayson, A. C., & Langer, R. (2004). Biodegradable polymers for controlled drug delivery. Advanced Drug Delivery Reviews, 56(11), 1685-1698.
- European Patent Office. EP1310031.
- Japanese Patent Office. JP2005150194.
- Li, L., & Huang, L. (2008). Recent advances in biodegradable polymer-based drug delivery systems. Materials Science & Engineering C, 28(3), 416-422.
